Publications by authors named "M A M M Ferraz"

Objective: to construct and validate the content of an inventory of ethical problems experienced by nurses in mobile pre-hospital care.

Method: a psychometric approach study, developed with the following stages: (1) instrument construction through a theoretical matrix based on deliberative bioethics, scoping review and online qualitative research; (2) content validity by judges; (3) pre-testing with Mobile Emergency Care Service nurses in various Brazilian states. For content validity analysis, the Content Validity Ratio was calculated (CVR>0.

View Article and Find Full Text PDF

Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).

View Article and Find Full Text PDF

This study aimed to identify the associations between socioeconomic factors, the social environment, and human papillomavirus (HPV) vaccine coverage among adolescents in the state of Minas Gerais (MG), Brazil. This ecological study utilized secondary data from 853 municipalities in MG, covering female adolescents from 2014 to 2022 and male adolescents from 2017 to 2022, as provided by the information system of the National Immunization Program. Spatial statistical analysis was conducted to assess spatial dependence and identify spatial clusters of municipalities with high and low HPV vaccine coverage.

View Article and Find Full Text PDF

The goal of this study was to evaluate characteristics associated with Pre-exposure Prophylaxis for HIV infection (PrEP) non-adherence or discontinuation in Brazil and assess the association between these outcomes and HIV seroconversion. We used linked national dispensing and pathology data to identify people aged 14+ years initiating PrEP in 2018. We estimated non-adherence using the proportion of days covered (PDC), defining non-adherence as PDC < 60%.

View Article and Find Full Text PDF

We developed a novel adeno-associated virus 5 gene therapy (AAV5-GLA) expressing human alpha-galactosidase A (GLA) under the control of a novel, small and strong, liver-restricted promoter. We assessed the preclinical potential of AAV5-GLA for treating Fabry disease, an X-linked hereditary metabolic disorder resulting from mutations in the gene encoding GLA that lead to accumulation of the substrates globotriaosylceramide and globotriaosylsphingosine, causing heart, kidney, and central nervous system dysfunction. Effects of intravenously administered AAV5-GLA were evaluated in (1) GLA-knockout mice aged 7-8 weeks (early in disease) and 20 weeks (nociception phenotype manifestation) and (2) cynomolgus macaques during an 8-week period.

View Article and Find Full Text PDF